UBS launches coverage on several big pharma names

|By:, SA News Editor

Some more big pharma coverage from UBS has the team initiating Novartis (NVS +0.4%) with a Buy rating. Started at Neutral are GlaxoSmithKline (GSK) and Sanofi (SNY -0.5%).

Earlier: AstraZeneca is initiated a Buy.